Circulating miRNAs as predictors for morbidity and mortality in coronary artery disease.


Journal

Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 02 05 2019
accepted: 02 07 2019
pubmed: 11 7 2019
medline: 10 3 2020
entrez: 11 7 2019
Statut: ppublish

Résumé

Micro ribonucleic acids (miRNAs) are small non-coding RNA molecules that control gene expression by translational inhibition. They have been identified to play a role in a multitude of physiological and pathophysiological cellular processes amongst others in the heart. Due to their ability to be released into the blood as well as their stability in body fluids, they appear suitable as biomarkers. This review discusses the role of selected miRNA that currently emerge as biomarkers for coronary artery disease, their potential to discriminate between different diseases, as well as how they might be used as predictive tools for cardiac events or disease outcome. Furthermore, we propose procedural steps of miRNA analysis, to allow better comparison between studies in the future.

Identifiants

pubmed: 31290056
doi: 10.1007/s11033-019-04963-9
pii: 10.1007/s11033-019-04963-9
doi:

Substances chimiques

Biomarkers 0
Cell-Free Nucleic Acids 0
MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

5661-5665

Références

GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963):117–171
doi: 10.1016/S0140-6736(14)61682-2
Benjamin EJ, Blaha MJ, Chiuve SE et al (2017) Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135(10):e146–e603
doi: 10.1161/CIR.0000000000000485 pubmed: 28122885 pmcid: 5408160
Bronze-da-Rocha E (2014) MicroRNAs expression profiles in cardiovascular diseases. Biomed Res Int 2014:985408
doi: 10.1155/2014/985408 pubmed: 25013816 pmcid: 4075084
Thygesen K, Alpert JS, Jaffe AS et al (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60(16):1581–1598
doi: 10.1016/j.jacc.2012.08.001 pubmed: 22958960
Jaffe AS, Ravkilde J, Roberts R et al (2000) It’s time for a change to a troponin standard. Circulation 102(11):1216–1220
doi: 10.1161/01.CIR.102.11.1216 pubmed: 10982533
Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350–355
doi: 10.1038/nature02871 pubmed: 15372042
Kloosterman WP, Plasterk RH (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11(4):441–450
doi: 10.1016/j.devcel.2006.09.009 pubmed: 17011485
Cai X, Hagedorn CH, Cullen BR (2004) Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10(12):1957–1966
doi: 10.1261/rna.7135204 pubmed: 15525708 pmcid: 1370684
van Rooij E, Olson EN (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117(9):2369–2376
doi: 10.1172/JCI33099 pubmed: 17786230 pmcid: 1952642
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297
doi: 10.1016/S0092-8674(04)00045-5 pubmed: 14744438
Maron BJ, Thompson PD, Puffer JC et al (1998) Cardiovascular preparticipation screening of competitive athletes: addendum: an addendum to a statement for health professionals from the Sudden Death Committee (Council on Clinical Cardiology) and the Congenital Cardiac Defects Committee (Council on Cardiovascular Disease in the Young), American Heart Association. Circulation 97(22):2294
doi: 10.1161/01.CIR.97.22.2294 pubmed: 9631885
Reid G, Kirschner MB, van Zandwijk N (2011) Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 80(2):193–208
doi: 10.1016/j.critrevonc.2010.11.004 pubmed: 21145252
Schulte C, Karakas M, Zeller T (2017) microRNAs in cardiovascular disease—clinical application. Clin Chem Lab Med 55(5):687–704
doi: 10.1515/cclm-2016-0576 pubmed: 27914211
Wang GK, Zhu JQ, Zhang JT et al (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31(6):659–666
doi: 10.1093/eurheartj/ehq013 pubmed: 20159880
Olivieri F, Antonicelli R, Lorenzi M et al (2013) Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol 167(2):531–536
doi: 10.1016/j.ijcard.2012.01.075 pubmed: 22330002
Gao W, He HW, Wang ZM et al (2012) Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis 15(11):55
doi: 10.1186/1476-511X-11-55
Gao H, Guddeti RR, Matsuzawa Y et al (2015) Plasma levels of microRNA-145 are associated with severity of coronary artery disease. PLoS ONE 10(5):e0123477
doi: 10.1371/journal.pone.0123477 pubmed: 25938589 pmcid: 4418743
Wang F, Long G, Zhao C et al (2013) Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med 23(11):222
doi: 10.1186/1479-5876-11-222
Chen MC, Chang TH, Chang JP et al (2016) Circulating miR-148b-3p and miR-409-3p as biomarkers for heart failure in patients with mitral regurgitation. Int J Cardiol 01(222):148–154
doi: 10.1016/j.ijcard.2016.07.179
Widera C, Gupta SK, Lorenzen JM et al (2011) Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 51(5):872–875
doi: 10.1016/j.yjmcc.2011.07.011 pubmed: 21806992
Ren J, Zhang J, Xu N et al (2013) Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS ONE 8(12):e80738
doi: 10.1371/journal.pone.0080738 pubmed: 24339880 pmcid: 3855151
Zeller T, Keller T, Ojeda F et al (2014) Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J 35(31):2106–2114
doi: 10.1093/eurheartj/ehu151 pubmed: 24727883
D’Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6):743–753
doi: 10.1161/CIRCULATIONAHA.107.699579 pubmed: 18212285
Bye A, Rosjo H, Nauman J et al (2016) Circulating microRNAs predict future fatal myocardial infarction in healthy individuals—the HUNT study. J Mol Cell Cardiol 97:162–168
doi: 10.1016/j.yjmcc.2016.05.009 pubmed: 27192016
Mayr B, Mueller EE, Schäfer C et al (2019) Exercise responsive micro ribonucleic acids identify patients with coronary artery disease. Eur J Prev Cardiol 26(4):348–355
doi: 10.1177/2047487318808014 pubmed: 30373378
Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G (2013) The impact of hemolysis on cell-free microRNA biomarkers. Front Genet 4:94
pubmed: 23745127 pmcid: 3663194
Mayr B, Mueller EE, Schäfer C, Breitenbach-Koller H, Schönfelder M, Niebauer J (2017) Pitfalls of analysis of circulating miRNA: role of hematocrit. Clin Chem Lab Med 55(5):622–625
doi: 10.1515/cclm-2016-0323 pubmed: 27768582
Ameling S, Kacprowski T, Chilukoti RK et al (2015) Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study. BMC Med Genom 14(8):61
doi: 10.1186/s12920-015-0136-7
Baggish AL, Hale A, Weiner RB et al (2011) Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J Physiol 589(Pt 16):3983–3994
doi: 10.1113/jphysiol.2011.213363 pubmed: 21690193 pmcid: 3179997

Auteurs

Barbara Mayr (B)

University Institute of Sports Medicine, Prevention and Rehabilitation and Research Institute of Molecular Sports Medicine and Rehabilitation, Paracelsus Medical University, Salzburg, Lindhofstraße 20, 5020, Salzburg, Austria. ba.mayr@salk.at.

Josef Niebauer (J)

University Institute of Sports Medicine, Prevention and Rehabilitation and Research Institute of Molecular Sports Medicine and Rehabilitation, Paracelsus Medical University, Salzburg, Lindhofstraße 20, 5020, Salzburg, Austria.

Hannelore Breitenbach-Koller (H)

Department of Bioscience, University of Salzburg, Salzburg, 5020, Salzburg, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH